<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6246">
  <stage>Registered</stage>
  <submitdate>14/03/2016</submitdate>
  <approvaldate>14/03/2016</approvaldate>
  <nctid>NCT02725567</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have a CFTR Gating Mutation</studytitle>
    <scientifictitle>A Phase 3, 2 Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have a CFTR Gating Mutation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>VX15-770-124</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ivacaftor

Experimental: Part A - Group 1: Participants 12 to &lt; 24 months
Group 2: Participants 6 to &lt; 12 months (enrollment begins after an assessment of data from Group 1)
Group 3: Participants 3 to &lt; 6 months (enrollment begins after an assessment of data from Group 2)
Group 4: Participants 0 to &lt; 3 months (enrollment begins after an assessment of data from Group 3)

Experimental: Part B - Group 5: Participants 12 to &lt; 24 months (enrollment begins after an assessment of data from Part A, Group 1
Group 6: Participants 6 to &lt; 12 months (enrollment begins after an assessment of data from Part A, Group 2
Group 7: Participants 0 to &lt; 6 months (enrollment begins after an assessment of data from Part A, Group 3, and also enrollment for subjects &lt; 3 months begins after review of data from Part A Group 4)


Treatment: drugs: ivacaftor


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Part A: Safety, as determined by number of subjects with adverse events (AEs), clinically relevant abnormal laboratory values (serum chemistry and hematology), standard 12 lead electrocardiograms (ECGs), vital signs, and ophthalmologic examinations</outcome>
      <timepoint>Day 1 up to Day 70</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part B: Safety, as determined by number of subjects with adverse events (AEs), clinically relevant abnormal laboratory values (serum chemistry and hematology), standard 12 lead electrocardiograms (ECGs), vital signs, and ophthalmologic examinations</outcome>
      <timepoint>Day 1 up to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part A: Peak concentrations (C3-6h) of ivacaftor, M1 ivacaftor, and M6 ivacaftor</outcome>
      <timepoint>after 4 days of ivacaftor treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part A: Trough concentrations (Ctrough) of ivacaftor, M1 ivacaftor, and M6 ivacaftor</outcome>
      <timepoint>after 4 days of ivacaftor treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Peak concentrations (C3-6h) of ivacaftor, M1 ivacaftor, and M6 ivacaftor</outcome>
      <timepoint>through Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Trough concentrations (Ctrough) of ivacaftor, M1 ivacaftor, and M6 ivacaftor</outcome>
      <timepoint>through Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Absolute change from baseline in sweat chloride using quantitative pilocarpine iontophoresis</outcome>
      <timepoint>through Week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Confirmed diagnosis of CF by sweat chloride value or CF mutation criteria.

          -  Must have 1 of the following 9 CFTR mutations on at least 1 allele: G551D, G178R,
             S549N, S549R, G551S, G1244E, S1251N, S1255P, or G1349D.

          -  Hematology, serum chemistry, and vital signs results at screening with no clinically
             significant abnormalities that would interfere with the study assessments, as judged
             by the investigator.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>24</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of any illness or condition that, in the opinion of the investigator, might
             confound the results of the study or pose an additional risk in administering study
             drug to the subject

          -  Colonization with organisms associated with a more rapid decline in pulmonary status
             at screening

          -  History of abnormal liver function or abnormal liver function at screening

          -  History of solid organ or hematological transplantation

          -  Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A
             within 2 weeks before Day 1

          -  Participation in a clinical study involving administration of either an
             investigational or a marketed drug within 30 days or 5 terminal half-lives before
             screening

          -  Hemoglobin (Hgb) &lt;9.5 g/dL at screening

          -  Chronic kidney disease of Stage 3 or above

          -  Presence of a non-congenital or progressive lens opacity or cataract at Screening

        Other protocol defined Inclusion/Exclusion Criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>35</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Parkville</hospital>
    <hospital> - South Brisbane</hospital>
    <hospital> - Westmead</hospital>
    <postcode> - Parkville</postcode>
    <postcode> - South Brisbane</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vertex Pharmaceuticals Incorporated</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety of ivacaftor treatment, and PK of
      ivacaftor and metabolites in subjects with cystic fibrosis (CF) who are &lt;24 months of age at
      treatment initiation and have a CF transmembrane conductance regulator (CFTR) gene gating
      mutation</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02725567</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Medical Information</name>
      <address />
      <phone>617-341-6777</phone>
      <fax />
      <email>medicalinfo@vrtx.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>